Alzheimer's research & therapy
-
Alzheimers Res Ther · Dec 2017
Randomized Controlled Trial Multicenter StudyA phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer's disease (AD). ⋯ The study was stopped early for futility, but dose-dependent effects observed in exploratory analyses on select clinical and biomarker endpoints suggest that higher dosing with gantenerumab may be necessary to achieve clinical efficacy.